Ad is loading...
ERNA
Price
$0.53
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
IBIO
Price
$2.45
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
Ad is loading...

ERNA vs IBIO

Header iconERNA vs IBIO Comparison
Open Charts ERNA vs IBIOBanner chart's image
Eterna Therapeutics
Price$0.53
Change-$0.00 (-0.00%)
Volume$315.62K
CapitalizationN/A
iBio
Price$2.45
Change-$0.00 (-0.00%)
Volume$150.89K
CapitalizationN/A
ERNA vs IBIO Comparison Chart
Loading...
ERNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
IBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ERNA vs. IBIO commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERNA is a Hold and IBIO is a Hold.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (ERNA: $0.52 vs. IBIO: $2.64)
Brand notoriety: ERNA and IBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERNA: 118% vs. IBIO: 194%
Market capitalization -- ERNA: $26.71M vs. IBIO: $24.15M
ERNA [@Biotechnology] is valued at $26.71M. IBIO’s [@Biotechnology] market capitalization is $24.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $450.11B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERNA’s FA Score shows that 0 FA rating(s) are green whileIBIO’s FA Score has 1 green FA rating(s).

  • ERNA’s FA Score: 0 green, 5 red.
  • IBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, IBIO is a better buy in the long-term than ERNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERNA’s TA Score shows that 4 TA indicator(s) are bullish while IBIO’s TA Score has 5 bullish TA indicator(s).

  • ERNA’s TA Score: 4 bullish, 4 bearish.
  • IBIO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both ERNA and IBIO are a good buy in the short-term.

Price Growth

ERNA (@Biotechnology) experienced а -37.72% price change this week, while IBIO (@Biotechnology) price change was +15.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.38%. For the same industry, the average monthly price growth was -4.87%, and the average quarterly price growth was +4.35%.

Reported Earning Dates

ERNA is expected to report earnings on May 11, 2023.

IBIO is expected to report earnings on May 15, 2023.

Industries' Descriptions

@Biotechnology (+2.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERNA($26.7M) has a higher market cap than IBIO($24.2M). IBIO YTD gains are higher at: 92.701 vs. ERNA (-71.031). IBIO has higher annual earnings (EBITDA): -12.95M vs. ERNA (-39.07M). IBIO has more cash in the bank: 11M vs. ERNA (4.26M). IBIO has less debt than ERNA: IBIO (4.23M) vs ERNA (33.5M). ERNA has higher revenues than IBIO: ERNA (598K) vs IBIO (175K).
ERNAIBIOERNA / IBIO
Capitalization26.7M24.2M110%
EBITDA-39.07M-12.95M302%
Gain YTD-71.03192.701-77%
P/E RatioN/AN/A-
Revenue598K175K342%
Total Cash4.26M11M39%
Total Debt33.5M4.23M791%
FUNDAMENTALS RATINGS
ERNA vs IBIO: Fundamental Ratings
ERNA
IBIO
OUTLOOK RATING
1..100
5175
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
85
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9761
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ERNA's Valuation (52) in the Medical Specialties industry is somewhat better than the same rating for IBIO (85) in the Biotechnology industry. This means that ERNA’s stock grew somewhat faster than IBIO’s over the last 12 months.

ERNA's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as IBIO (100) in the Biotechnology industry. This means that ERNA’s stock grew similarly to IBIO’s over the last 12 months.

IBIO's SMR Rating (98) in the Biotechnology industry is in the same range as ERNA (100) in the Medical Specialties industry. This means that IBIO’s stock grew similarly to ERNA’s over the last 12 months.

IBIO's Price Growth Rating (61) in the Biotechnology industry is somewhat better than the same rating for ERNA (97) in the Medical Specialties industry. This means that IBIO’s stock grew somewhat faster than ERNA’s over the last 12 months.

IBIO's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for ERNA (100) in the Medical Specialties industry. This means that IBIO’s stock grew significantly faster than ERNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ERNAIBIO
RSI
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
75%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 12 days ago
84%
Bullish Trend 1 day ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
88%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
ERNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
IBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PCB21.440.64
+3.08%
PCB Bancorp
VHC5.150.14
+2.79%
VirnetX Holding Corp
GMS101.702.60
+2.62%
GMS
MTB221.124.50
+2.08%
M&T Bank Corp
BCSF16.740.10
+0.60%
Bain Capital Specialty Finance

ERNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERNA has been loosely correlated with CGEN. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ERNA jumps, then CGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERNA
1D Price
Change %
ERNA100%
-2.29%
CGEN - ERNA
39%
Loosely correlated
-2.76%
MDGL - ERNA
36%
Loosely correlated
+5.53%
IBIO - ERNA
32%
Poorly correlated
+7.76%
SMMT - ERNA
31%
Poorly correlated
+3.15%
CYTK - ERNA
29%
Poorly correlated
+3.00%
More

IBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBIO has been loosely correlated with ELVAF. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if IBIO jumps, then ELVAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBIO
1D Price
Change %
IBIO100%
+7.76%
ELVAF - IBIO
39%
Loosely correlated
N/A
VOR - IBIO
36%
Loosely correlated
-0.77%
REPL - IBIO
34%
Loosely correlated
+35.11%
ADMA - IBIO
31%
Poorly correlated
-0.56%
NUVB - IBIO
29%
Poorly correlated
+3.70%
More